MEDITE Cancer Diagnostics, Inc. (MDIT) (the “Company”), specializing in the development, manufacturing and marketing of molecular biomarkers and premium medical devices for detection, risk assessment and diagnosis of cancer and precancerous conditions, today announced the closing of a $5.4 million private financing with GPB Debt Holdings, resulting in gross proceeds net of discount of $4.9 million.
— MEDITE Cancer Diagnostics Reports Closing of $5.4 Million Private Financing